Replacing transplant and chemo with CI-based therapy and ISRT maintains survival, reduces side effects in younger patients ...

Adcetris is also indicated as monotherapy or in combination with chemotherapy for the treatment of certain types of classical Hodgkin lymphoma, anaplastic large cell lymphoma and peripheral T-cell ...

In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.

There are lots of good dividend stocks to consider stepping into here, but only a few truly great income-producing prospects.

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Takeda and Seattle Genetics are closing in on a new front-line use for their Adcetris in classical Hodgkin lymphoma after a successful late-stage trial. The positive results from the phase 3 ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Corvus Pharmaceuticals' Soquelitinib shows promise for PTCL & more, but financial risks and competition raise concerns. Learn more about CRVS stock here.

Pfizer's Q4/24 results showed significant improvements, with total revenue up 21.9% YoY and adjusted diluted EPS increasing ...

All the latest breaking news on United States. Browse ibtimes archives of photos, videos and articles on United States.

NICE has ruled that Takeda’s Hodgkin’s lymphoma treatment Adcetris should no longer be funded on the NHS, saying there isn’t enough evidence to support its use. The treatment is a ‘legacy ...

WearOptimo, a healthcare technology company developing next-generation Microwearable sensors for hydration and biomarker monitoring, today introduced its Advisory Board comprised of globally ...